Vous êtes sur la page 1sur 52

Departamento de Patentes e Informacin Tecnolgica

Unidad de Informacin Tecnolgica

NANOFRMACOS
134 Resultados
Solicitudes de Patente publicadas a nivel mundial en los ltimos 30 dias.

Datos actualizados a 04/03/2016 [16:26:00]

CHELATED NANOCERIA FOR THE TREATMENT OF OXIDATIVE STRESS


N publicacin EP2989054A2 02/03/2016
CERION ENTPR LLC [US]
Solicitantes
A process for making cerium-containing nanoparticles with biocompatible stabilizers is described, wherein an aqueous reaction
Resumen
mixture comprising cerous ion, citric acid, a stabilizer (chelator) selected from the group consisting of nitrilotriacetic acid,
ethylene glycol tetraacetic acid and diethylenetriaminepentaacetic acid, and an oxidant, is provided, followed by a heating step to
effectively form the nanoparticles. These biocompatible nanoparticles can be used to treat oxidative stress related diseases and
events, such as ischemic stroke.
Process of nanoprecipitation of proteins and peptides with low molecular weight
N publicacin EP2990033A1 02/03/2016
CARLINA TECHNOLOGIES [FR]
Solicitantes
La prsente invention concerne un procd de prparation non dnaturant de nanoprcipits de peptides ou protines ou de
Resumen
nanocoprcipits de peptides ou protines et d'ions mtalliques, dans lequel ladite protine ou ledit peptide est de poids
molculaire infrieur 15 kDa, avantageusement infrieur 10 kDa, plus avantageusement infrieur 8 kDa. Ledit procd
comprend une tape de prparation d'un mlange d'une solution aqueuse de peptides ou protines, d'un non-solvant du peptide ou
de la protine, et ventuellement un sel mtallique hydrosoluble. La prsente invention concerne galement un nanoprcipit
susceptible d'tre obtenu par le procd selon l'invention, ainsi qu'une composition pharmaceutique le comprenant, pour leur
utilisation dans le traitement ou la prvention du diabte.
MONODISPERSE GLYCOGEN AND PHYTOGLYCOGEN NANOPARTICLES AND USE THEREOF AS ADDITIVES IN
COSMETICS, PHARMACEUTICALS, AND FOOD PRODUCTS
N publicacin EP2988725A1 02/03/2016
MIREXUS BIOTECHNOLOGIES INC [CA]
Solicitantes
Monodisperse glycogen or phytoglycogen nanoparticles are
Resumen
polyfunctional additives suitable for use in aqueous or alcohol-based
cosmetic, pharmaceutical, or food formulations. The nanoparticles
may be isolated from various sources (such as corn), and are
optionally modified with a range of organic moieties (such as octenyl
succinic acid). The monodisperse and particulate nature of the
glycogen/phytoglycogen is believed to render such materials useful as
rheological modifiers (including modulation of thixotropic behaviour),
stabilizers of organic and biological materials, and photostabilizers in
sunscreens.

Alertas Tecnolgicas

- 1 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

MONODISPERSE GLYCOGEN AND PHYTOGLYCOGEN NANOPARTICLES AND USE THEREOF AS ADDITIVES IN


COSMETICS, PHARMACEUTICALS, AND FOOD PRODUCTS
N publicacin EP2989156A1 02/03/2016
MIREXUS BIOTECHNOLOGIES INC [CA]
Solicitantes
Monodisperse glycogen or phytoglycogen nanoparticles are
Resumen
polyfunctional additives suitable for use in aqueous or alcohol-based
cosmetic, pharmaceutical, or food formulations. The nanoparticles
may be isolated from various sources (such as corn), and are
optionally modified with a range of organic moieties (such as octenyl
succinic acid). The monodisperse and particulate nature of the
glycogen/phytoglycogen is believed to render such materials useful as
rheological modifiers (including modulation of thixotropic behaviour),
stabilizers of organic and biological materials, and photostabilizers in
sunscreens.

POLYPEPTIDE PARTICLE AND METHOD FOR PRODUCING SAME


N publicacin EP2990414A1 02/03/2016
SPIBER INC [JP]
Solicitantes
This polypeptide particle derives from spider silk protein, and the
Resumen
average particle size of the particle is no greater than 1000 nm. This
method for producing a polypeptide particle includes: a solution
production step for obtaining a polypeptide solution by dissolving the
polypeptide in at least one solvent selected from the group consisting
of DMSO, DMF, and the result of adding an inorganic salt thereto; a
step for obtaining an aqueous solution of the polypeptide by means of
a substitution to a water-soluble solvent in the solution generated in
the solution production step; and a step for drying the aqueous
solution of the polypeptide. As a result, the characteristics of the
polypeptide particle are clarified, and provided are: a polypeptide that
can be applied to a cosmetic or the like and is superior in application
to a living body; and a method for producing same.

Alertas Tecnolgicas

- 2 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

VITAMIN D RECEPTOR/SMAD GENOMIC CIRCUIT GATES FIBROTIC RESPONSE


N publicacin EP2988752A1 02/03/2016
SALK INST FOR BIOLOGICAL STUDI [US]
Solicitantes
UNIV SYDNEY [AU]
The present disclosure provides compositions that include a
Resumen
nanoparticle and a compound that increases the biological activity of
the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of
using such compounds to increase retention or storage of vitamin A,
vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell.
Such methods can be used to treat or prevent fibrosis.

ANTISEPTIC VETERINARY FORMULATION AND METHODS FOR USE THEREOF


N publicacin EP2990034A1 02/03/2016
OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU NANOBIOTEKH [RU]
Solicitantes
DENISOV ALBERT NIKOLAEVICH [RU]
The invention relates to veterinary science, in particular, to antiseptic formulations with a broad spectrum of activity, and
Resumen
concerns a drug for treating wound surfaces, inflamed mucosa, and postoperative sutures. The invention can be used for
prophylaxis of postoperative complications, for treatment and prophylaxis of mastitis and endometritis, conjunctivitis, gingivitis,
diarrhoea, rhinitis, and otitis in pets and farm animals, inter alia, large and small cattle, poultry, cats, and dogs. The antiseptic
veterinary formulation comprises nano-sized particles of silver and benzyl-dimethyl-[3-(myristoylamino)propyl]-ammonium
chloride. The methods for treating and prophylaxis of mastitis and endometritis, conjunctivitis, gingivitis, diarrhoea, rhinitis, and
otitis in pets and farm animals comprise the use of the antiseptic veterinary formulation comprising nano-sized particles of silver
and benzyl-dimethyl-[3-(myristoylamino)propyl]-ammonium chloride.
BIOCOMPATIBLE INFINITE COORDINATION POLYMER NANOPARTICLE-NUCLEIC ACID CONJUGATES FOR
ANTISENSE GENE REGULATION
N publicacin WO2016028995A1 25/02/2016
UNIV NORTHWESTERN [US]
Solicitantes
Disclosed herein are metal-ligand complexes containing polynucleotides, compounds for making the same, and methods of using
Resumen
the same.
ARIPIPRAZOLE PRODRUG COMPOSITIONS
N publicacin WO2016026822A1 25/02/2016
ALKERMES PHARMA IRELAND LTD [IE]
Solicitantes
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size
Resumen
(Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the
surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The
surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in
formulation. Also described are methods of treatment using the aforementioned composition.

Alertas Tecnolgicas

- 3 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

BIODEGRADABLE COPOLYMERS, SYSTEMS INCLUDING THE COPOLYMERS, AND METHODS OF FORMING AND
USING SAME
N publicacin US2016051469A1 25/02/2016
PARK DAEWON [US]
Solicitantes
KAHOOK MALIK [US]
FAMILI AMIN [US]
Therapeutic agent delivery systems, which include a
Resumen
thermally-sensitive copolymer and optionally a therapeutic agent, are
disclosed. The copolymer is water soluble and biodegradable and, in
accordance with exemplary embodiments, includes hydrophobic and
hydrophilic portions. The systems may include supplemental
compounds, such as polymeric nanoparticles, micelle compounds, or a
combination thereof, to further provide sustained release of the
therapeutic agent.

THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING
SAME
N publicacin US2016051522A1 25/02/2016
BIND THERAPEUTICS INC [US]
Solicitantes
The present disclosure generally relates to therapeutic nanoparticles.
Resumen
Exemplary nanoparticles disclosed herein may include about 0.2 to
about 20 weight percent of epothilone, e.g. epothilone B; and about 50
to about 99 weight percent biocompatible polymer.

Alertas Tecnolgicas

- 4 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE


N publicacin US2016051635A1 25/02/2016
UNIV WASHINGTON [US]
Solicitantes
The present disclosure provides oxygen-carrying nanoparticles,
Resumen
methods of making the nanoparticles, and methods of using the
nanoparticles to carry oxygen in blood.

MESOPOROUS SILICA-COATED NANOPARTICLES


N publicacin US2016051471A1 25/02/2016
UNIV MINNESOTA [US]
Solicitantes
The present invention relates to mesoporous silica coated nanoparticles comprising a metal oxide nanoparticle core; and a
Resumen
mesoporous silica shell encapsulating metal oxide core; wherein said mesoporous silica shell and the metal oxide core are not in
full contact. The nanoparticles of the invention are useful as diagnostic and therapeutic agents.
SELF-ANTIGEN DISPLAYING NANOPARTICLES TARGETING AUTO-REACTIVE IMMUNE FACTORS AND USES
THEREOF
N publicacin WO2016028965A1 25/02/2016
UNIV CALIFORNIA [US]
Solicitantes
The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target
Resumen
auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles
can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune
regulation.
PROTEIN/OLIGONUCLEOTIDE CORE-SHELL NANOPARTICLE THERAPEUTICS
N publicacin WO2016028940A1 25/02/2016
UNIV NORTHWESTERN [US]
Solicitantes
The present disclosure is directed to core-shell nanoparticles, compositions comprising core-shell nanoparticles, and methods of
Resumen
their use.
CONJUGATED POLYMER NANOPARTICLES AND MANUFACTURING METHOD THEREOF
N publicacin WO2016027952A1 25/02/2016
UNIV YONSEI IACF [KR]
Solicitantes
The present invention relates to conjugated polymer nanoparticles and a manufacturing method thereof, wherein the conjugated
Resumen
polymer nanoparticles comprise conjugated polymer, fatty acid and amphipathic polymer. The conjugated polymer nanoparticles
can be doped in a neutral environment, and thus have high electrical conductivity in a neutral environment such as in vivo, and
are capable of having high light absorbance properties in a near infrared region.

Alertas Tecnolgicas

- 5 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NANOSCALE ARTIFICIAL ANTIGEN PRESENTING CELLS


N publicacin US2016051698A1 25/02/2016
UNIV JOHNS HOPKINS [US]
Solicitantes
This disclosure provides nano-scale Artificial Antigen Presenting
Resumen
Cells (aAPC), which deliver stimulatory signals to lymphocytes,
including cytotoxic lymphocytes, for use as a powerful tool for
immunotherapy.

NANODELIVERY DEVICE FOR THERAPEUTIC LOADING OF CIRCULATING ERYTHROCYTES


N publicacin US2016051697A1 25/02/2016
UNIV OKLAHOMA STATE [US]
Solicitantes
According to one embodiment, a person's own RBCs can be recruited as secondary bioscavenger carriers in vivo using a
Resumen
nanopolymer-BChE complex, with an affinity ligand (antibody or peptide) for selective targeting to the RBCs and a
cell-penetrating peptide for uptake into the RBCs. A general approach according to an embodiment involves parenteral
administration of the nanodevice to gain access to the systemic circulation, which then seeks out and attaches to the person's
RBCs, followed by transport into the RBCs (to minimize clearance from the circulation), leading to long-term circulation of the
bioscavenger enzymes and thus protection against intoxication.

Alertas Tecnolgicas

- 6 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

BIODEGRADABLE BIONANOPARTICLES FOR RELEASING THE GSE24-2 PEPTIDE, METHOD FOR THE PRODUCTION
THEREOF, AND USE OF SAME
N publicacin US2016051485A1 25/02/2016
CONSEJO SUPERIOR INVESTIGACION [ES]
Solicitantes
UNIV MADRID AUTONOMA [ES]
UNIV PAIS VASCO [ES]
CT DE INVESTIGACI\u00D3 BIOMEDICA EN RED DE ENFERMEDADES RARAS CIBERER [ES]
The invention relates to biodegradable PLGA bionanoparticles
Resumen
encapsulating the GSE24-2 peptide with telomerase activity, and to
pharmaceutical, cosmetic and biotechnological compositions
comprising same. The pharmaceutical compositions are useful for
treating diseases presenting a telomerase deficiency, such as
dyskeratosis congenita, and diseases presenting ageing characteristics,
such as Werner syndrome, Rothmund Thompson syndrome, and other
diseases where there is DNA damage such as ataxia telangiectasia.
The relation also relates to the method for producing said
bionanoparticles by means of a w/o/w double emulsion technique.

SUBSTANCE-CONTAINING VESICLE, AND PRODUCTION METHOD THEREFOR


N publicacin US2016051484A1 25/02/2016
JAPAN SCIENCE & TECH AGENCY [JP]
Solicitantes
Provided is a monodisperse agglomerate of a substance-containing
Resumen
vesicle filled with a substance at a concentration higher than
conventionally possible. A mixed solution, in which a target substance
is included in an aqueous medium, is mixed with a monodisperse
agglomerate of a crosslinked vesicle comprising a prescribed polymer
which includes a first polymer, i.e. a block copolymer having
uncharged hydrophilic segments and first charged segments, and a
second polymer having second charged segments carrying a charge
opposite to that of the first charged segments, and in which the first
polymer and/or the second polymer are/is crosslinked. As a result, the
crosslinked vesicle is made to contain the target substance.

Alertas Tecnolgicas

- 7 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

DRUG CARRIER HAVING SELF-ASSEMBLED 3-D NUCLEIC ACID NANOSTRUCTURE


N publicacin US2016051483A1 25/02/2016
KOREA INST SCI & TECH [KR]
Solicitantes
The present invention relates to a molecule delivery technology and a
Resumen
carrier technology, which may selectively deliver a material to a
desired specific cell and living tissue. The present invention may be
utilized in the field of a drug carrier which effectively delivers an
imaging probe and a therapeutic agent to an affected part.

Alertas Tecnolgicas

- 8 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

MULTISTAGE DELIVERY OF ACTIVE AGENTS


N publicacin US2016051481A1 25/02/2016
FERRARI MAURO [US]
Solicitantes
TASCIOTTI ENNIO [US]
SAKAMOTO JASON [US]
UNIV TEXAS [US]
UNIV OHIO STATE RES FOUND [US]
Multistage delivery vehicles are disclosed which include a first stage
Resumen
particle and a second stage particle. The first stage particle is a micro
or nanoparticle that contains the second stage particle. The second
stage particle includes an active agent, such as a therapeutic agent or
an imaging agent. The multistage delivery vehicle allows sequential
overcoming or bypassing of biological barriers. The multistage
delivery vehicle is administered as a part of a composition that
includes a plurality of the vehicles. Methods of making the multistage
delivery vehicles are also provided.

Alertas Tecnolgicas

- 9 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NEUTRALLY-CHARGED SYNTHETIC PLATELETS TO MITIGATE COMPLEMENT RESPONSE


N publicacin EP2986323A1 24/02/2016
UNIV CASE WESTERN RESERVE [US]
Solicitantes
The invention provides for compositions comprising nanoparticles
Resumen
comprising a core, water-soluble polymer and an RGD peptide and a
poloxamer.

NANOSCALE COATINGS FOR ENCAPSULATION OF BIOLOGICAL ENTITIES


N publicacin EP2986282A1 24/02/2016
UNIV CALIFORNIA [US]
Solicitantes
Methods, systems, and devices are disclosed for encapsulating
Resumen
biological entities with preservation of their biological activity. In one
aspect, a method of encapsulating a biological entity includes
templating a biocompatible material onto a biological structure to
form a coating structure enclosing the biological structure, the coating
structure having a size in the nanometer range, in which the coated
biological structure preserves its biological activity within the coating
structure. In some implementations of the method, the biological
structure includes a virus and the biocompatible material includes
silica.

Alertas Tecnolgicas

- 10 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

processo de obteno de nanopartculas lipdicas slidas, nanopartculas lipdicas slidas e seu uso
N publicacin BR102014017316A2 23/02/2016
UNIV ESTADUAL PAULISTA JULIO D [BR]
Solicitantes
processo de obtenao de nanopartculas lipdicas slidas, nanoparticulas lipidicas slidas e seu uso. a presente inveno descreve
Resumen
um processo de obteno de nanoparticulas lipidicas slidas com trans-resveratrol (res) por sonicao, utilizando lipidio
peguilado, bem como as nanoparticulas obtidas e seu uso na terapia antitumoral do melanoma. SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE
N publicacin BRPI1007515A2 23/02/2016
NOVARTIS AG [CH]
Solicitantes
A solid oral dosage pharmaceutical formulation of
Resumen
(R)-2-Amino-7-[4-fluoro-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
or its salt; and a surfactant or an acid.

Cpocob polyhehiya hahokapcyl ppobiotikoB


N publicacin RU2014131359A 20/02/2016
Cpocob polyhehiya hahokapcyl ppobiotikoB, xapaktepizyyushchiicya tem, hto B kahectBe obolohki hahokapcyl icpolbzyetcya
Resumen
albGihat hatpiya ppi ix polyhehii fiziko-ximiheckim metodom ocazhdehiya hepactBopitelem c icpolbzoBahiem Gekcaha B
kahectBe ocaditelya.

Alertas Tecnolgicas

- 11 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COMPOSITIONS FOR INHIBITING INFLAMMATION IN A SUBJECT WITH A SPINAL CORD INJURY AND METHODS OF
USING THE SAME
N publicacin US2016045439A1 18/02/2016
PIXARBIO CORP [US]
Solicitantes
Provided herein are compositions for inhibiting inflammation in a
Resumen
subject with a spinal cord injury comprising one or more agents
capable of specifically reducing TNF-[alpha] signaling and a
biodegradable carrier. Further provided herein are compositions for
inhibiting inflammation in a subject with a spinal cord injury
comprising one or more agents capable of modulating MCP-1
signaling and a biodegradable carrier. Methods of treating
inflammation in a subject having a spinal cord injury and kits for
producing the compositions are also disclosed.

DENDRIMER COMPOSITIONS AND USE IN TREATMENT OF NEUROLOGICAL AND CNS DISORDERS


N publicacin WO2016025745A1 18/02/2016
UNIV JOHNS HOPKINS [US]
Solicitantes
KENNEDY KRIEGER INST INC [US]
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic
Resumen
administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form of dendrimer
nanoparticles comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one
therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of neurodegenerative, neurodevelopmental
or neurological disorders such as Rett syndrome or autism spectrum disorders, D6 generation dendrimers provide significantly
enhanced uptake into areas of brain Injury, providing a means for diagnosis as well, as drug delivery.
COMPOSITIONS FOR STABILIZING AND DELIVERING PROTEINS
N publicacin WO2016025911A1 18/02/2016
UNIV BROWN [US]
Solicitantes
THERAPYX INC [US]
Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are
Resumen
embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The
crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate
bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.
INJECTABLE FORMULATIONS OF ASENAPINE
N publicacin WO2016023658A1 18/02/2016
ALRISE BIOSYSTEMS GMBH [DE]
Solicitantes
The invention provides nano- and/or microparticles comprising asenapine or a pharmaceutically acceptable salt thereof, wherein
Resumen
said asenapine or said pharmaceutically acceptable salt thereof is embedded in a polymer matrix or encapsulated by a polymer
shell, wherein the polymer matrix or the polymer shell comprises a polymer selected from polylactide, polyglycolide, and
polyester copolymers comprising copolymerized units of lactic acid and/or glycolic acid, as well as a process for their production.
Moreover, the invention provides pharmaceutical compositions comprising these particles.

Alertas Tecnolgicas

- 12 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

METHODS OF TREATING PANCREATIC CANCER


N publicacin JP2016505018A 18/02/2016
Provided herein are methods for the treatment of metastatic pancreatic
Resumen
cancer comprising administration of a composition comprising
nanoparticles comprising a taxane (such as paclitaxel) and a carrier
protein in combination with gemcitabine.

Nanoparticles with enhanced mucosal penetration or decreased inflammation


N publicacin AU2016200683A1 18/02/2016
UNIV JOHNS HOPKINS
Solicitantes
Nanoparticles formed by emulsion of one or more core polymers, one
Resumen
or more surface altering materials, and one or more low molecular
weight emulsifiers have been developed. The particles are made by
dissolving the one or more core polymers in an organic solvent,
adding the solution of the one or more core polymers to an aqueous
solution or suspension of the emulsifier to form an emulsion, and then
adding the emulsion to a second solution or suspension of the
emulsifier to effect formation of the nanoparticles. In the preferred
embodiment, the molecular weight of the emulsifiers is less than 1500,
1300, 1200, 1000, 800, 600, or 500 amu. Preferred emulsifiers include
cholic acid sodium salt, dioctyl sulfosuccinate sodium,
hexadecyltrimethyl ammonium bromide, saponin, TWEEN TM 20,
TWEEN TM 80, and sugar esters.; The surface altering materials are
present in an amount effective to make the surface charge of the
particles neutral or essentially neutral when the one or more
emulsifiers are charged. The emulsifiers have an emulsification
capacity of at least about 50%, preferably at least 55, 60, 65, 70, 75,
80, 85, 90, or 95%.

Alertas Tecnolgicas

- 13 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES


N publicacin AU2016200506A1 18/02/2016
HARVARD COLLEGE
Solicitantes
The invention provides compositions and methods for treating or
Resumen
imaging stenosis, stenotic lesions, occluded lumens, embolic
phenomena or thrombotic disorders. The invention further provides
compositions and methods for treating internal hemorrhage.

PEPTIDE CONJUGATED PARTICLES


N publicacin AU2014306603A1 18/02/2016
UNIV NORTHWESTERN
Solicitantes
The present invention provides compositions comprising
Resumen
peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG)
particles In particular, PLG particles are surface-functionalized to
allow for coupling of peptide molecules to the surface of the particles
(e.g., for use in eliciting induction of immunological tolerance).

Alertas Tecnolgicas

- 14 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NANOPARTICLES AND NANOPARTICLE COMPOSITION, AND METHOD FOR PRODUCING NANOPARTICLES AND
NONPARTICLE COMPOSITION
N publicacin AU2014303394A1 18/02/2016
UNIV KINKI
Solicitantes
OTSUKA PHARMA CO LTD
The present invention relates to a nanoparticle composition obtained
Resumen
by a method characterized in dissolving a sparingly-soluble compound
in water or the like under high temperature and high pressure, and
crushing the suspension or the like containing uniform crystals
obtained by cooling the obtained solution.

NANOPARTICLES WITH EFFECTS ON ENDOTHELIAL FUNCTION AND MEMBRANE PERMEABILITY


N publicacin US2016045573A1 18/02/2016
YEN RICHARD C K [US]
Solicitantes
The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a
Resumen
hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the
patient. The protein spheres are bound with fibrinogen molecules in vitro or in vivo. The fibrinogen-coated albumin spheres
provide improved hemostatic function of a residual concentration of platelets of the patient resulting in decreasing mortality rate
or decreasing morbidity of the patient. The fibrinogen-coated albumin spheres protect an endothelial function of an endothelial
cell of a blood vessel of the patient resulting in improved permeability control across predetermined tissues in the patient, thereby
counteracting an effect of the hemorrhagic virus on a wall of the blood vessel.
DELIVERY OF BIOACTIVE, NANOENCAPSULATED ANTIOXIDANTS
N publicacin WO2016025394A2 18/02/2016
UNIV LOUISIANA STATE [US]
Solicitantes
IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY [RO]
SABLIOV CHRISTINA M [US]
ASTETE CARLOS E [US]
BODOKI EDE [RO]
VOSTINARU OLIVIU [RO]
SAMOILA OVIDIU CIPRIAN [RO]
DINTE ELENA [RO]
Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive
Resumen
form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein
such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the
nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue,
bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive,
bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing
conditions such as age-related macular degeneration or cataracts.

Alertas Tecnolgicas

- 15 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COATED PARTICLES FOR DRUG DELIVERY


N publicacin WO2016025922A1 18/02/2016
DANA FARBER CANCER INST INC [US]
Solicitantes
In one aspect, a particle comprising a core containing at least one pharmaceutically active agent and a coating covering the
Resumen
surface of the particle that comprises a biocompatible adhesive polymer is provided. The core may comprise two or more
components, such as two pharmaceutically active agents or a pharmaceutically active agent and a major constituent of the core,
having at least one dissimilar chemical or physical property (e.g., molecular weight, solubility, cLogP). In some such
embodiments, placement of the uncoated core in certain environments results in the rapid release of a component (e.g., a
pharmaceutically active agent) from and/or destabilization and breakdown of the core. In some embodiments, the biocompatible
adhesive polymer in the coating acts as a molecular glue to stabilize the core and/or alter the release kinetics of at least one
pharmaceutically active agent.
COMPOSITIONS FOR INHIBITING INFLAMMATION IN A SUBJECT WITH A SPINAL CORD INJURY AND METHODS OF
USING THE SAME
N publicacin WO2016025789A1 18/02/2016
PIXARBIO CORP [US]
Solicitantes
Provided herein are compositions for inhibiting inflammation in a subject with a spinal cord injury comprising one or more agents
Resumen
capable of specifically reducing TNF-[alpha] signaling and a biodegradable carrier. Further provided herein are compositions for
inhibiting inflammation in a subject with a spinal cord injury comprising one or more agents capable of modulating MCP-1
signaling and a biodegradable carrier. Methods of treating inflammation in a subject having a spinal cord injury and kits for
producing the compositions are also disclosed.
METHODS FOR KILLING CANCER CELLS AND CELLULAR IMAGING USING MAGNETO-ELECTRIC NANO-PARTICLES
AND EXTERNAL MAGNETIC FIELD
N publicacin WO2016025768A1 18/02/2016
LIANG PING [US]
Solicitantes
This invention provides methods for achieving high-specificity killing of targeted cells using Magneto-Electric Nano-Particles
Resumen
(MENPs). Embodiments comprise injecting into a patients body manufactured MENPs that have a higher tendency to accumulate
near or attach to targeted cells through one or more physical forces and/or biological mechanisms; and applying a magnetic field
to the MENPs to generate actions that are sufficient to cause death of the targeted cells.
POLYESTER STEREOCOMPLEXES, COMPOSITIONS COMPRISING SAME, AND METHODS OF MAKING AND USING
SAME
N publicacin WO2016025675A1 18/02/2016
UNIV CORNELL [US]
Solicitantes
Compositions comprising stereocomplexes of enantiomeric polymer chains having individual repeat units formed from the
Resumen
reaction of an epoxide and cyclic anhydride. The compositions can be made by mixing two types of enantiomeric polymer chains
having opposite absolute stereochemistry. The compositions can be used in applications such as biomedical applications and drug
delivery applications.
CARBON NANOTUBE-DRUG DELIVERY SYSTEM FOR TARGETING CANCER STEM CELLS, METHOD FOR
PREPARATION OF SAME, AND USE OF SAME
N publicacin WO2016023456A1 18/02/2016
INST PHARM & TOXICOLOGY AMMS [CN]
Solicitantes
The present invention relates to a drug delivery system, comprising a drug-loaded carbon nanotube formed by a carbon nanotube
Resumen
and drug molecules adsorbed to the surface of the carbon nanotube, a modifying material capable of enhancing the water
solubility and biocompatibility of the drug delivery system, and a targeting molecule. The present invention also relates to a
preparation method, and use, of the drug delivery system. The present invention provides a new type of strategy for selective
targeting and effective removal of cancer stem cells, which is advantageous to the fundamental prevention of cancer recurrence
and metastasis caused by cancer stem cells.

Alertas Tecnolgicas

- 16 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

BIODEGRADABLE AND CLINICALLY-COMPATIBLE NANOP ARTICLES AS DRUG DELIVERY CARRIERS


N publicacin US2016046936A1 18/02/2016
1GLOBE HEALTH INST LLC [US]
Solicitantes
The present invention relates to the composition of a nanoparticle
Resumen
based on a magnesium salt, and methods of drug delivery using the
nanoparticle. A preferred embodiment uses magnesium phosphate,
with or without a shell to deliver aiRNA and/or siRNA. The
nanoparticles of the present invention are also effective when
administered orally.

NANOMETER-SIZED PRODRUGS OF NSAIDS TO TREAT TRAUMATIC BRAIN INJURY


N publicacin US2016045620A1 18/02/2016
CEDARS SINAI MEDICAL CENTER [US]
Solicitantes
The present invention describes methods of delivering derivatives of
Resumen
non-steroidal anti-inflammatory drugs (NSAIDs) and nanospheres
thereof as well as therapeutic agents to the injuried brain tissue in
subjects with tramatic brain injury. The invention also provides
methods of treating traumatic brain injury and related conditions. The
invention further provides methods of diagnosing traumatic brain
injury.

Alertas Tecnolgicas

- 17 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

PARTICLES HAVING PEG-YLATED SURFACES MODIFIED FOR LYMPHATIC TRAFFICKING


N publicacin US2016045613A1 18/02/2016
UNIV NORTH CAROLINA [US]
Solicitantes
The subject matter disclosed herein is directed to modifying and
Resumen
utilizing properties of micro and/or nano-particles to traffic the
particles to lymph nodes. As described herein, the properties include
size, charge, and surface characteristics of the particles.

FUNCTIONALIZED NANOPARTICLES FOR MEDICAL TREATMENTS


N publicacin US2016045612A1 18/02/2016
UNIV MASSACHUSETTS [US]
Solicitantes
A class of functionalized nanoparticles useful in medical treatments is
Resumen
described. The nanoparticles have an attached carbohydrate that is
selected on the basis that a cell to be treated ingests as a consequence
of the presence of the carbohydrate. The nanoparticles have an
attached chemical that if inside the cell is capable of treating the cell
(e.g., curing a disease condition in the cell, killing the cell if it is
pathogenic, or improving the health of the cell). The nanoparticle
carries the chemical preferentially into the cell because the cell will
ingest the carbohydrate, and thereby allows the nanoparticle and the
chemical into itself.

Alertas Tecnolgicas

- 18 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

LONG CIRCULATING NANOPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS


N publicacin US2016045608A1 18/02/2016
BIND THERAPEUTICS INC [US]
Solicitantes
The present disclosure is directed in part to a biocompatible
Resumen
nanoparticle composition comprising a plurality of non-colloidal long
circulating nanoparticles, each comprising a a-hydroxy
polyester-co-polyether and a therapeutic agent, wherein such disclosed
compositions provide a therapeutic effect for at least 12 hours.

NANOPARTICLES, COMPOSED OF STEROL AND SAPONIN FROM QUILLAJA SAPONARIA MOLINA PROCESS FOR
PREPARATION AND USE THEREOF AS CARRIER FOR AMPHIPATIC OF HYDRPHOBIC MOLECULES IN FIELDS OF
MEDICINE INCLUDING CANCER TREATMENT AND FOOD RELATED COMPOUNDS
N publicacin US2016045595A1 18/02/2016
MOREINX AB [SE]
Solicitantes
A nanoparticle comprising at least one sterol, e.g. cholesterol and a
Resumen
component from Quillaja Saponaria Molina (QuilQ) selected from
quillaja saponin, characterized in that said nanoparticles do not
comprise a phospholipid and in that the sterol molecule is bound by a
hydrophobic bond between a hydroxyl group of the sterol and terpene
moieties in a Quil A micelle and by an hydrophilic ester bond between
a sterol OH and COOH or aldehyde groups in the QuilA micelle. It
also relates to a composition comprising the nanoparticles, and the use
thereof as adjuvant, especially in vaccines, as carriers for amphipathic
or hydrophobic molecules and as agents for treatment of cancer.
Further, it regards a method for producing the phospholipid-free
nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.

Alertas Tecnolgicas

- 19 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

HYDROGEL VACCINE FORMULATIONS


N publicacin US2016045585A1 18/02/2016
SIGMOID PHARMA LTD [IE]
Solicitantes
This invention relates to compositions for delivering one or more
Resumen
active ingredients, and more particularly to compositions, e.g. beads,
comprising a matrix material which matrix material comprises a
microorganism. In particular, the invention relates to compositions
comprising a microorganism selected from live, killed, attenuated and
inactivated microorganisms. The matrix material may also comprise a
surfactant and may further comprise an adjuvant. The invention
further relates to the manufacture and use of such compositions, and to
other subject matter.

DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION


N publicacin US2016045486A1 18/02/2016
MAILMAN RICHARD B [US]
Solicitantes
Trans-hexahydrobenzo[a]phenanthridines of the formula (I) wherein
Resumen
X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are
disclosed. Pharmaceutical formulations including such compounds,
and methods of using such compounds for treating a patient suffering
from dopamine-related dysfunction of the central or peripheral
nervous system are also disclosed.

Alertas Tecnolgicas

- 20 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COMBINATION THERAPEUTIC NANOPARTICLES


N publicacin US2016045445A1 18/02/2016
UNIV GEORGIA [US]
Solicitantes
Nanoparticles that include a chemotherapeutic agent and an
Resumen
anti-inflammatory are particularly cytotoxic to prostate cancer cells.

ORAL PHARMACEUTICAL COMPOSITION COMPRISING TASTE-MASKED N-ACETYLCYSTEINE


N publicacin EP2983650A1 17/02/2016
HERMES ARZNEIMITTEL GMBH [DE]
Solicitantes
The invention provides coated particles with taste-masked N-acetylcysteine. The particles comprise a core with the active
Resumen
ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release
profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical
compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby
preventing the degradation of the thermolabile active ingredient.
COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS
N publicacin EP2983789A1 17/02/2016
UNIV NEBRASKA [US]
Solicitantes
In
accordance
with
the
instant
invention,
Resumen
nanopartides/nanoformulations comprising at least one therapeutic
agent and at least one surfactant linked to gp120 are provided. In a
particular embodiment, the surfactant is an amphiphilic block
copolymer, polysorbate, phospholipid, derivative thereof, or
combination thereof. In a particular embodiment, the surfactant is an
amphiphilic block copolymer. In a particular embodiment, the
nanopartides/nanofonnulations further comprise other surfactants
linked to at least one other targeting ligand. An individual nanopartide
may comprise targeted and non-targeted surfactants. In a particular
embodiment, the therapeutic agent is an antiviral, antiretroviral, or
anti-HIV compound. In a particular embodiment, the surfactant is
PLGA-PEG. Pharmaceutical compositions comprising at least
nanoparticle of the instant invention and at least one pharmaceutically
acceptable carrier are also provided.

Alertas Tecnolgicas

- 21 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COATED PARTICLES AND COMPOSITIONS COMPRISING SAME


N publicacin KR20160015335A 12/02/2016
The invention provides species of lipid, protein, and/or cationic
Resumen
molecule coated active agents and compositions comprising the coated
particles. The compositions can be personal care compositions such as
anti-dandruff shampoo or conditioner, skin care compositions, creams,
gels, toothpastes, mouth washes, and chewing gums.

METHODS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE COMPOUNDS IN NANOPARTICULATE FORM


N publicacin JP2016026220A 12/02/2016
A method for producing a composition comprising nanoparticles of a
Resumen
biologically active compound.

Alertas Tecnolgicas

- 22 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NANOPARTICLE COMPOSITIONS OF ALBUMIN AND PACLITAXEL


N publicacin JP2016504362A 12/02/2016
The present invention provides compositions (such as pharmaceutical compositions) comprising nanoparticles comprising
Resumen
albumin and paclitaxel. The compositions have a specific albumin polymer/monomer profile and are particularly suitable for use
in treating diseases such as cancer.
REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS
N publicacin KR20160015293A 12/02/2016
This invention relates to repeated administration of antigen-specific
Resumen
immunotherapeutics using protocols, or elements thereof, that do not
induce immunosuppression. In some embodiments, the protocol has
been previously shown not to induce immunosuppression in a subject.

METHODS OF ENHANCING DRUG DELIVERY AND EFFECTIVENESS OF THERAPEUTIC AGENTS


N publicacin AU2016200171A1 11/02/2016
ABRAXIS BIOSCIENCE LLC
Solicitantes
The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as
Resumen
methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by
co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane
with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting
patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising
nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the
target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the
co-administration of the taxane nanoparticle composition in the target tissue (referred to as "the drug uptake capability"). Also
provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.
REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES
N publicacin WO2016020545A1 11/02/2016
DSM IP ASSETS BV [NL]
Solicitantes
The present invention relates to biodegradable polyesteramides (PEAs) comprising hydrophobic alpha -amino acids, diols,
Resumen
aliphatic dicarboxylic acids and optionally diamines whereby at least one of the dicarboxylic acids, diols or diamines comprises
disulphide linkages. The present invention also relates to the use of the polyesteramides in medical applications such as cancer
treatment, ophthalmic applications, therapeutic cardiovascular applications, veterinary applications, pain management
applications, MSK applications and vaccine delivery compositions. The present invention also relates to a drug delivery
composition comprising the PEA's and to a drug delivery system such as micro-or nanoparticles, micelles, liposomes,
polymerosomes, micro- and nanogels, polymerosomes or nanotubes.

Alertas Tecnolgicas

- 23 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

METHOD FOR THE SITE-SPECIFIC COVALENT CROSS-LINKING OF ANTIBODIES TO SURFACES


N publicacin US2016041157A1 11/02/2016
UNIV PENNSYLVANIA [US]
Solicitantes
This invention relates to to conjugate antibody, drug and nanoparticle
Resumen
compositions and methods of generating the same. This invention
further relates to methods of using same for imaging, diagnosing or
treating a disease.

MEROPENEM DERIVATIVES AND USES THEREOF


N publicacin US2016039823A1 11/02/2016
KALA PHARMACEUTICALS INC [US]
Solicitantes
The present invention provides novel derivative of [beta]-lactam
Resumen
antibiotics, such as meropenem. The inventive compounds include
compounds of Formula (I), and pharmaceutically acceptable salts,
solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers,
isotopically labeled derivatives, and prodrugs thereof. Also provided
are particles (e.g., nanoparticles) and pharmaceutical compositions
thereof that are mucus penetrating. The inventive particles and
pharmaceutical compositions may be useful in delivering an inventive
compound to the respiratory tract of a subject. The invention further
provides methods of using and kits including the inventive
compounds, particles thereof, and/or pharmaceutical compositions
thereof for treating and/or preventing a pulmonary disease (e.g., a
respiratory tract infection).

Alertas Tecnolgicas

- 24 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

METHOD OF MONITORING THE RELEASE FROM LIPOSOMES OF A PRODUCT OF INTEREST USING


SUPERPARAMAGNETIC NANOPARTICLES.
N publicacin US2016038616A1 11/02/2016
NANOBIOTIX [FR]
Solicitantes
CENTRE NAT RECH SCIENT [FR]
UNIV BORDEAUX SEGALEN [FR]
The present application relates to a method of monitoring the
Resumen
membrane permeabilization of liposome and the incidental release of
a compound of interest.

NANOFIBRE AND BIOACTIVE COMPOSITIONS AND RELATED METHODS


N publicacin US2016038611A1 11/02/2016
ACTIVE FIBRES LTD [NZ]
Solicitantes
Described herein are compositions in nanofibre form including one or
Resumen
more bioactive compounds releasably incorporated thereon. In one
embodiment a composition is described comprising at least one
nanofibre and at least one bioactive compound. The nanofibres are
formed from a base material that is solubilised with the bioactive or
bioactives in an aqueous based solvent solution and the base material
and bioactives are together spun via electrospinning to form dry fibres
with the bioactives chemically bonded to the nanofibres and the
bioactives remaining stable during storage of the composition under
ambient conditions substantially free of moisture. On exposure to
moisture, the nanofibres dissolve, thereby releasing the bioactives.

COMPOSITIONS AND METHODS FOR IMAGING AND TREATMENT


N publicacin US2016038610A1 11/02/2016
UNIV NEW YORK [US]
Solicitantes
Provided are compositions and methods for transport, monitoring the transport, and controlled release of active agents. The
Resumen
compositions comprise surface functionalized iron oxide nanoparticles. The iron oxide nanoparticles are surface functionalized
with cucurbitril[7] macrocycles. The cavity formed by the CB[7] macrocycles can be used for storage and transport of active
agents. The active agents may be imaging agents or may be therapeutic agents which can be released by applying an alternating
magnetic field at desired locations.

Alertas Tecnolgicas

- 25 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

MULTISTAGE NANOPARTICLES
N publicacin US2016038609A1 11/02/2016
GEN HOSPITAL CORP [US]
Solicitantes
MASSACHUSETTS INST TECHNOLOGY [US]
Multistage nanostructures, e.g., for delivery of agents such as imaging
Resumen
agents and therapeutic agents to tumor vasculature.

SILICA-BASED MESOPOROUS CARRIER AND DELIVERY METHOD OF USING THE SAME


N publicacin US2016038608A1 11/02/2016
UNIV NAT TAIWAN [TW]
Solicitantes
Mesoporous carriers for delivering targets into a cell are provided. The mesoporous carriers comprise hollow silica nanospheres
Resumen
(HSN) or mesoporous silica nanoparticles (MSN) and the targets bound to or encapsulated by the hollow silica nanospheres or the
mesoporous silica nanoparticles. The targets includes at least two different targets, and the targets may include peptides, proteins,
enzymes and/or enzymatic mimetics.
NANOPARTICLE DRUG DELIVERY SYSTEMS
N publicacin US2016038607A1 11/02/2016
UNIV NOTRE DAME DU LAC [US]
Solicitantes
The invention provides pharmaceutical compositions and method of
Resumen
using the compositions, wherein the compositions comprise liposomes
or micelles that contain one or more targeting peptides and/or
anticancer drugs. In various embodiments, the components of the
liposomes can include a) a phospholipid and optionally a lipid that is
not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol
(EG)-lipid conjugate wherein the peptide is a targeting ligand, and d)
one or more drug-conjugated lipid, encapsulated drugs, or a
combination thereof. The peptide- EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The
ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment
can be conjugated to one or more lysine moieties.

Alertas Tecnolgicas

- 26 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

PORPHYRIN MODIFIED TELODENDRIMERS


N publicacin US2016038605A1 11/02/2016
UNIV CALIFORNIA [US]
Solicitantes
The present invention provides amphiphilic telodendrimers that
Resumen
aggregate to form nanocarriers characterized by a hydrophobic core
and a hydrophilic exterior. The nanocarrier core may include
amphiphilic functionality such as cholic acid or cholic acid
derivatives, and the exterior may include branched or linear
poly(ethylene glycol) segments. Nanocarrier cargo such as
hydrophobic drugs and other materials may be sequester in the core
via non-covalent means or may be covalently bound to the
telodendrimer building blocks. Telodendrimer structure may be
tailored to alter loading properties, interactions with materials such as
biological membranes, and other characteristics.

MODIFIED POLY(BETA-AMINO ESTER)S FOR DRUG DELIVERY


N publicacin US2016038598A1 11/02/2016
INST QU\u00CDMIC DE SARRI\u00C0 CETS FUNDACI\u00D3 PRIVADA [ES]
Solicitantes
Disclosed are polymers that are poly(beta-amino ester)s (PBAEs)
Resumen
modified with at least one oligopeptide. The polymers may be used in
any field where polymers have been found useful including in medical
fields, particularly in drug delivery. The polymers are particularly
useful in delivering a polynucleotide such as DNA, RNA and siRNA,
a small molecule or a protein. Also disclosed are compositions
comprising said polymers and an active agent, methods of
encapsulating an agent in a matrix of said polymers, and said
polymers and compositions for use in medicine.

Alertas Tecnolgicas

- 27 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC AND IMAGING AGENTS TO THE SINUSES AND
MIDDLE EAR
N publicacin US2016038590A1 11/02/2016
LI JIAN-DONG [US]
Solicitantes
UNIV GEORGIA STATE RES FOUND [US]
The present invention features compositions and methods for targeted
Resumen
delivery of a therapeutic or imaging agent to a site accessible through
the nose or mouth that may be difficult to effectively and efficiently
treat otherwise (e.g., the middle ear, sinuses, or lung). The therapeutic
or imaging agent is deposited onto a magnetic nanoparticle that is
drawn through a passage or tissue that leads away from the nose or
mouth by a magnetic field applied over the targeted site (e.g., by
magnets within the ear canal or surrounding the ear).

COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE INDUCTION TO FACTOR VIII REPLACEMENT THERAPIES
IN SUBJECTS WITH HEMOPHILIA A
N publicacin US2016038575A1 11/02/2016
HAPLOMICS INC [US]
Solicitantes
UNIV CALIFORNIA [US]
US DEPT VETERANS AFFAIRS [US]
Tolerance inducing peptide (TIP) derived from the amino acid
Resumen
reference locus (AARL) within a FVIII replacement product (FVIIIrp)
based on the differences between the expression product of a subject's
F8 gene (sFVIII) and the FVIIIrp to provide tolerance induction
before, during, and/or after a FVIII replacement therapy in a subject
suffering from Hemophila A is disclosed. Methods of deriving,
making, and using the TIP are also disclosed. In some embodiments,
the TIP is associated with a nanoparticle, e.g., PLGA or PLGA-PEMA
nanoparticle.

Alertas Tecnolgicas

- 28 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

RAPIDLY ADAPTABLE NANO THERAPEUTICS FOR TREATMENT OF INFECTIOUS DISEASE


N publicacin US2016038528A1 11/02/2016
TECHULON INC [US]
Solicitantes
The invention relates to rapidly adaptable nanotherapeutics. The
Resumen
therapeutics are nucleic acid molecules, such as, RNA, DNA, or
modified-DNA. The nucleic acid therapeutics are preferably
administered as a nanoparticle composition, further containing one or
more synthetic polymers. The therapeutics are rapidly adaptable
because the identification and design of the polynucleotide sequence
containing the therapeutic sequence is based upon rapid computerimplemented bioinformatics and nucleic acid synthesis protocols. The
rapid adaptable protocols differ from traditional methods of antibiotic
and antipathogenic drug development, which are slow and do not
address drug resistance issues. Furthermore, the invention
encompasses a facility with dedicated apparatus for practicing the
invention in military theater or where emerging pathogenic threats are
located.; This facility may be mobile and transportable as a dedicated
unit.

NANOCAPSULES OF PROTAMINE
N publicacin US2016038433A1 11/02/2016
UNIV SANTIAGO COMPOSTELA [ES]
Solicitantes
The present invention relates to the design and development of
Resumen
nanocapsule systems for the administration of active substances,
wherein the nanocapsules of the system have a mean diameter less
than 1 [mu]m and are characterized by comprising (a) a protamine
shell, (b) an oily core, and one or more surfactants characterized by
having a hydrophilic-lipophilic ratio greater than 8, provided that said
surfactant is not a phospholipid.

NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS


N publicacin US2016038418A1 11/02/2016
UNIV NORTH CAROLINA [US]
Solicitantes
Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The
Resumen
nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic
materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter.

Alertas Tecnolgicas

- 29 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

RADIOGRAPHIC CONTRAST AGENTS FOR TEMPORAL SUBTRACTION AND DUAL-ENERGY X-RAY IMAGING
N publicacin US2016038111A1 11/02/2016
UNIV PENNSYLVANIA [US]
Solicitantes
Contrast agents for x-ray imaging including stabilized metal
Resumen
nanoparticles and encapsulated nanoparticles, as well as methods for
imaging tissue with these agents, are disclosed. Also disclosed are
methods of dual energy x-ray imaging using metal nanoparticle
contrast agents or encapsulated metal nanoparticles.

THERMOSTABLE, CHROMATOGRAPHICALLY PURIFIED NANO-VLP VACCINE


N publicacin WO2016022916A2 11/02/2016
U S ARMY MEDICAL RES INST OF INFECTIOUS DISEASES DEPT OF THE ARMY [US]
Solicitantes
CARRA JOHN HOWARD [US]
BAVARI SINA [US]
HONE DAVID [US]
In this application is described a method for preparing nano-VLP composition, thereby permitting purification using
Resumen
chromatography and filtration. The nano-VLP composition has a more uniform size range of filovirus particles, roughly 230 nm
diameter, allowing ease of manipulation of the composition, while retaining GP conformational integrity and the antigenic
effectiveness of the vaccine. Additionally, the nano-VLP can be lyophilized without loss of nano- VLP structure, or GP
immunogenicity. Lyophilized nano-VLP have greatly enhanced thermostability, allowing the creation of a filovirus nano-VLP
vaccine without a cold chain requirement.
SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS
N publicacin WO2016022987A1 11/02/2016
OHIO STATE INNOVATION FOUNDATION [US]
Solicitantes
Disclosed are compositions that contain a plurality of biocompatible self-assembling molecules that transform from isolated
Resumen
molecules or spherical micelles while in blood serum into cylindrical nanofibers in the acidic extracellular environment of tumors,
which can be used to achieve a higher relative concentration of imaging, drug delivery, or radiotherapeutic agents at the tumor
site compared to non-tumor tissues. This transition is rapid and reversible, indicating the system is in thermodynamic equilibrium.
NANOPARTICLES FOR DRUG DELIVERY
N publicacin WO2016022845A1 11/02/2016
UNIV LOUISVILLE RES FOUND [US]
Solicitantes
NANTZ MICHAEL H [US]
KNIPP RALPH [US]
The invention provides therapeutic magnetic nanoparticles containing a therapeutic agent connected to a magnetic nanoparticle
Resumen
core through a stable functional group and a linker that can be induced to release the therapeutic agent from the core, through
hydrolysis of the functional group. Also provided are methods for making nanoparticles, and methods for using nanoparticles.
COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION OF
TUMORS
N publicacin WO2016022805A1 11/02/2016
VINDICO NANOBIO TECHNOLOGY INC [US]
Solicitantes
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM,
Resumen
leading to widespread shutdown of vascular flow, hemorrhage, and necrosis. PEM constructs are developed that incorporate large
amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties
induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.

Alertas Tecnolgicas

- 30 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

UNIFORM NANOCOMPOSITIONS, METHODS OF MAKING THE SAME, AND USES OF THE SAME
N publicacin WO2016022503A1 11/02/2016
NVIGEN INC [US]
Solicitantes
A uniform cluster of nanocompositions suspended in a liquid media is provided. Methods of making such nanocompositions, and
Resumen
uses of such nanocompositions are also provided. The nanocompositions can be used for nucleic acid extraction and diagnostic
assays, for immunoassays, for cell separation, identification and modulation, for controlled functional molecule protection and
release, for assays used in the clinic (companion diagnostics) or in the therapeutic development process (drug target validation),
and in a system for transcatheter arterial chemoembolization, and demonstrate superior performance due to the uniform property
or monodispersity.
ANTI-CANCER AGENT FOR USE IN COMBINATION THERAPY OF HIGH INTENSITY FOCUSED ULTRASOUND THERAPY
AND ANTI-CANCER AGENT THERAPY
N publicacin WO2016021551A1 11/02/2016
UNIV TOKYO WOMENS MEDICAL [JP]
Solicitantes
The present invention provides a cancer therapy method having reduced adverse side effects. Specifically, an anti-cancer agent
Resumen
comprising an anthracycline is used in such a manner that the anthracycline can be administered to a cancer patient at a dose of
0.5 to 7.5 mg/kg body weight in a combination therapy of a high intensity focused ultrasound therapy at a radiation intensity of
320 to 700 W/cm2 and an anti-cancer agent therapy.
PHARMACEUTICAL COMPOSITIONS OF POLYMERIC NANOPARTICLES
N publicacin WO2016020697A1 11/02/2016
CIPLA LTD [IN]
Solicitantes
KING LAWRENCE [GB]
The present invention relates to pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs.
Resumen
CORE-SHELL CROSSLINKED HYALURONIC ACID GEL PARTICLES, PRODUCTION METHOD FOR SAME, AND MEDICAL
MATERIAL
N publicacin AU2014288252A1 11/02/2016
DENKA COMPANY LTD
Solicitantes
These core-shell crosslinked hyaluronic acid gel particles are
Resumen
core-shell crosslinked hyaluronic acid gel particles having higher
equilibrium swelling ratio at the surface than at the center, an
inflection point being present on the curve of change of the
equilibrium swelling ratio plotted from the center to the surface,
wherein the probe pushing force to a depth of 800 nm from the surface
is 20 nN or less.

Alertas Tecnolgicas

- 31 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

metodologia de avaliao da toxicidade de oncofrmacos e de nanoestruturas em ocitos e embries bovinos


N publicacin BR102014016268A2 10/02/2016
UNIV FED DE PELOTAS [BR]
Solicitantes
resumo da patente de inveno para: metodologia de avaliao da toxicidade de oncofrmacos e de nanoestruturas em ocitos e
Resumen
embries bovinos a presente inveno refere-se metodologia de anlise da toxicidade causada por novos oncofrmacos e
nanoestruturas baseado em avaliaes de ocitos e embries bovinos, e mais particularmente, refere-se metodologia empregada
como modelo de diagnstico do efeito deletrio causado em clulas no tumorais por frmacos de uso oncolgico humano,
servindo como suporte para os testes in vitro de efetividade do princpio ativo. a presente inveno tem como objetivo principal
contribuir com o desenvolvimento tecnolgico na teraputica do cncer, a partir da identificao de novos frmacos com
potencial antitumoral.; para isso a presente inveno abrange metodologia de anlise da toxicidade celular causada por estes
oncofrmacos e nanoestruturas, baseado em avaliaes de em clulas germinativas e embrionrias. em particular, proposta uma
sequncia de mtodos de avaliao, permitindo que uma triagem de formulaes e concentraes dos oncofrmacos e
nanoestruturas ainda em estgio de avaliao in vitro. uma bateria de testes de desenvolvimento in vitro; seguidos de colorao
para determinar viabilidade e integridade de membrana celular, formao de espcies reativas de oxignio, estgio do ciclo
celular e apoptose, anlises de expresso de genes relacionados aos processos de apoptose, estresse oxidativo e crescimento
celular; permitindo assim, o diagnstico de efeitos deletrios causados em clulas no tumorais de forma prtica, rpida e
eficiente em laboratrios de cultivo celular e embriologia, incrementando os testes in vitro pr-clnicos de oncofrmacos e
nanoestruturas. 1/2
PREPARATION OF BONE-SEEKING SUPERPARAMAGNETIC IRON NANOPARTICLES AS CONTRAST AGENTS AND
METHODS FOR USING THE SAME
N publicacin EP2981296A2 10/02/2016
UNIV ALBERTA [CA]
Solicitantes
Described herein are compositions having a nanoparticle that is
Resumen
conjugated to at least one bone targeting moiety, wherein the bone
targeting moiety is bonded to the nanoparticle by a linker, wherein the
nanoparticle contains iron, and wherein the compositions are neutral
or pharmaceutically acceptable salts or esters. Also described herein
are methods of making these compositions. In one aspect, the
nanoparticles serve as contrast agents for magnetic resonance imaging
of bone metabolism.; The compounds, compositions, and methods
described herein can be used in a number of therapeutic applications
including diagnosing or monitoring fracture and/or the progress of
conditions associated with bone loss, which include, but are not
limited to, osteoporosis, Paget' s disease, osteolytic tumors,
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
osteoarthritis, osteopenia, and hypercalcemia.

Alertas Tecnolgicas

- 32 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

MESOPOROUS ALUM NANOPARTICLES AS UNIVERSAL PLATFORM FOR ANTIGEN ADSORPTION, PRESENTATION,


AND DELIVERY
N publicacin EP2981249A1 10/02/2016
STC UNM [US]
Solicitantes
SANDIA CORP [US]
The present invention relates to mesoporous alum nanoparticles which
Resumen
can be used as a universal platform for antigen adsorption,
presentation and delivery to provide immune compositions, including
vaccines and to generate an immune response (preferably, both
humoral and cell mediated immune response), preferably a heightened
immune response to the presentation of one or more antigens to a
patient or subject.

NANOPARTICLES FOR DRUG DELIVERY COMPRISING ALBUMIN HAVING A POLYMER CHAIN COUPLED THERETO
N publicacin EP2981291A1 10/02/2016
NEWSOUTH INNOVATIONS PTY LTD [AU]
Solicitantes
The invention provides a dispersion of assemblies. The assemblies
Resumen
comprise an albumin derivative comprising albumin having a polymer
chain coupled thereto, wherein the assemblies comprise a core
comprising the polymer chains and a shell comprising the albumin. A
process for making the dispersion and methods of using the dispersion
are also described.

USE OF POLYMERIC EXCIPIENTS FOR LYOPHILIZATION OR FREEZING OF PARTICLES


N publicacin RU2014128590A 10/02/2016
Provided herein are use of polymeric excipients, specifically polyvinyl alcohols, optionally in conjunction with sugars, as
Resumen
cryoprotectants to prevent aggregation of PEG- containing particles. Also provided are PEG-containing particles comprising such
polymeric excipients.

Alertas Tecnolgicas

- 33 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

METAL OXIDE NANOPARTICLE-BASED MAGNETIC RESONANCE IMAGING CONTRAST AGENT WITH A CENTRAL
CAVITY
N publicacin EP2981293A1 10/02/2016
INTRON BIOTECHNOLOGY INC [KR]
Solicitantes
The present invention relates to a magnetic resonance imaging (MRI)
Resumen
contrast agent, particularly an MRI contrast agent derived from
nanoparticle that is porous first metal-doped second metal oxide
nanoparticle with a central cavity, and a method for producing the
same. The MRI contrast agent made in accordance with the present
invention can be used not only as a drug-delivery agent for therapy but
also as an MRI contrast agent for diagnosis.

OIL-IN-WATER EMULSION COMPOSITION


N publicacin EP2982364A1 10/02/2016
FUJIFILM CORP [JP]
Solicitantes
Provided is an oil-in-water emulsion composition containing an oil phase, which contains oil having an I/O value of equal to or
Resumen
less than 0.15 and an oil-soluble antioxidant, and a water phase which contains a water-soluble antioxidant, in which the average
particle size of emulsion particles is equal to or less than 120 nm.
ANTIBIOTIC PROTOCELLS AND RELATED PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT
N publicacin EP2981611A1 10/02/2016
STC UNM [US]
Solicitantes
SANDIA CORP [US]
The invention provides novel antibiotic protocells comprising
Resumen
mesoporous nanoparticles encapsulated within a lipid bi- or
multilayer. The nanoparticles have pore sizes and surface chemistries
that enable facile adsorption and intracellular presentation of
antibiotics which are effective in the treatment of a wide variety of
bacterial infections, including F. tularensis, B. pseudomallei and P.
aeruginosa-related infections. Related pharmaceutical compositions
and methods of treatment are also provided.

Alertas Tecnolgicas

- 34 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NOVEL NANOPARTICLE COMPOSITIONS


N publicacin EP2981285A1 10/02/2016
ALLERTEIN THERAPEUTICS LLC [US]
Solicitantes
The present invention provides, among other things, nanoparticle
Resumen
compositions including a plurality of nanoparticles, each of which is
comprised of a biodegradable or biocompatible polymer arranged in a
nanoparticle structure defining an internal lumen and an external
surface and one or more of a preparation of hydrophilic cellular
components and a preparation of hydrophobic cellular components. In
some embodiments, the preparation of hydrophilic cellular
components is encapsulated within the internal lumen and the
preparation of hydrophobic cellular components is associated with the
external surface. Various methods of making and using disclosed
nanoparticle compositions are also provided.

METAL OXIDE NANOPARTICLE-BASED T1-T2 DUAL-MODE MAGNETIC RESONANCE IMAGING CONTRAST AGENT
N publicacin EP2981294A1 10/02/2016
INTRON BIOTECHNOLOGY INC [KR]
Solicitantes
The present invention relates to a magnetic resonance imaging (MRI)
Resumen
contrast agent, particularly a metal oxide nanoparticle-based T1-T2
dual-mode MRI contrast agent that can be used not only as a T1 MRI
contrast agent but also as a T2 MRI contrast agent, and a method for
producing the same. The metal oxide nanoparticle-based T1-T2
dual-mode MRI contrast agent can provide more accurate and detailed
information associated with disease than single MRI contrast agent by
the beneficial contrast effects in both T1 imaging with high tissue
resolution and T2 imaging with high feasibility on detection of a
lesion.

Alertas Tecnolgicas

- 35 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NANOCAPSULES OF PROTAMINE
N publicacin JP2016503780A 08/02/2016
The present invention relates to the design and development of
Resumen
nanocapsule systems for the administration of active substances,
wherein the nanocapsules of the system have a mean diameter less
than 1 [mu]m and are characterized by comprising (a) a protamine
shell, (b) an oily core, and one or more surfactants characterized by
having a hydrophilic-lipophilic ratio greater than 8, provided that said
surfactant is not a phospholipid.

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS
N publicacin HK1207594A1 05/02/2016
UTI LIMITED PARTNERSHIP [CA]
Solicitantes
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the
Resumen
present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T
cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore,
the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate
autoimmune diseases.

Alertas Tecnolgicas

- 36 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING MATERIALS FOR FOLLICULAR DELIVERY
N publicacin HK1207572A1 05/02/2016
GEN HOSPITAL CORP [US]
Solicitantes
The present invention provides compositions comprising energy (e.g.,
Resumen
light) absorbing submicron particles (e.g., nanoparticles comprising a
silica core and a gold shell) and methods for delivering such particles
via topical application. This delivery is facilitated by application of
mechanical agitation (e.g. massage), acoustic vibration in the range of
10 Hz - 20 kHz, ultrasound, alternating suction and pressure, and
microjets.

CONSTRUCTS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASES AND COLON CANCER
N publicacin HK1207581A1 05/02/2016
UNIV GEORGIA STATE RES FOUND [US]
Solicitantes
The present invention features, inter alia, constructs for the delivery of
Resumen
therapeutic and diagnostic agents to a patient. The constructs can
include a nanoparticle, a targeting agent that specifically binds a
targeted tissue or cell, a therapeutic moiety, and a hydrogel. The
constructs can be used in the treatment and diagnosis of bowel
diseases, including inflammatory bowel disease (IBD) and colon
cancer. In one embodiment, the therapeutic agent is a nucleic acid that
mediates RNA inhibition (RNAi), and the invention is directed to
treatments for IBD that combine the positive aspects of such agents
{e.g., siRNAs) with the safety of a biodegradable polymeric delivery
system to facilitate specific targeting of colonic tissues and cells. As
the constructs can be formulated for oral administration, they are well
tolerated and offer advantages with regard to patient compliance.

Alertas Tecnolgicas

- 37 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

BREAST CANCER THERAPY BASED ON HORMONE RECEPTOR STATUS WITH NANOPARTICLES COMPRISING TAXANE
N publicacin JP2016020398A 04/02/2016
The present invention relates to methods and kits for the treatment of
Resumen
breast cancer based on hormone receptor status of progesterone
receptor and estrogen receptor comprising the administration of a
taxane alone, in combination with at least one other and other
therapeutic agents, as well as other treatment modalities useful in the
treatment of breast cancer. In particular, the invention relates to the
use of nanoparticles comprising paclitaxel and albumin (such as
Abraxane TM ) either alone or in combination with other
chemotherapeutic agents or radiation, which may be used for the
treatment of breast cancer which does not express estrogen receptor
and/or progesterone receptor.

NANOPARTICLE COMPRISING HYDROPHOBIC DRUG CONJUGATED TO CATIONIC POLYMER AND HYDROPHILIC


DRUG CONJUGATED TO ANIONIC POLYMER
N publicacin KR20160013342A 04/02/2016
The present invention relates to a nanoparticle including a hydrophobic drug conjugated to a cationic polymer and a hydrophilic
Resumen
drug conjugated to an anionic polymer, a method of preparing the same and a pharmaceutical use thereof. The nanoparticle
according to an embodiment of the present invention may deliver the hydrophilic drug and the hydrophobic drug at the same time,
and may control an initial drug burst. Further, the nanoparticle according to an embodiment of the present invention is specific to
a cancer cell environment, and thus selective diagnosis or treatment of cancer cells is possible.
NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT
N publicacin AU2015271950A1 04/02/2016
ABRAXIS BIOSCIENCE LLC
Solicitantes
Abstract The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering
Resumen
nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms)
comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides
combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles
that comprise rapamycin or a derivative thereof and a second therapy.
WATER-CONTAINING FLUID COMPOSITION, METHOD FOR PRODUCING SAME, PROCESSED LYSOZYME AND/OR
SALT THEREOF, AND METHOD FOR PRODUCING SAME
N publicacin WO2016017784A1 04/02/2016
KEWPIE CORP [JP]
Solicitantes
UNIV TOKYO NAT UNIV CORP [JP]
In this water-containing fluid composition, which includes a processed lysozyme and/or salt thereof, the fluorescence intensity
Resumen
defined below is 5,000 or more, and the processed lysozyme and/or salt thereof is dissolved into the water-containing fluid
composition while being in contact with a polar organic solvent, wherein the content of the polar organic solvent in the
water-containing fluid composition is 55-90 mass%, inclusive. Fluorescence intensity: Fluorescence intensity obtained by
measuring, under the conditions of an excitation wavelength of 390 nm (excitation bandwidth of 10 nm) and a fluorescence
wavelength of 470 nm (fluorescence bandwidth of 10 nm), a solution obtained by reacting, for 30 minutes at room temperature, a
solution obtained by adding 25 [mu]L of an 8 mM 1,8-anilinonaphthalene sulfonate methanol solution to 5 mL of a dilute solution
obtained by diluting the water-containing fluid composition with a phosphate buffer solution (pH 7.0) such that the concentration
of the processed lysozyme and/or salt thereof is 0.05 mass% in terms of solid content and the phosphate concentration is 0.2M

Alertas Tecnolgicas

- 38 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG


N publicacin WO2016016908A1 04/02/2016
SUN PHARMA ADVANCED RES CO LTD [IN]
Solicitantes
The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the
Resumen
method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin
particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size
distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an
aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2
micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70
nanometers to 900 nanometers.
Fatty-acid-binding alhumin-drug nanoparticle lyophilized preparation and preparation method thereof
N publicacin WO2016015522A1 04/02/2016
TIANJIN PEGYLATT BIOTECHNOLOGY CO LTD [CN]
Solicitantes
The invention discloses a fatty-acid-binding alhumin-drug
Resumen
nanoparticle lyophilized preparation and a preparation method thereof;
by use of high affinity and stable binding characteristics of fatty acids
and albumin specific sites, nanoparticles using the fatty acids as the
core are prepared under the effects of high shearing forces, one or a
plurality of ''water-insoluble'' or ''water-soluble '' drug in the form of
''solution'' or ''ultrafine nanoparticles'' is/are ''packaged'' or ''bound'' to
obtain various types of nanoparticles suspensions, and the lyophilized
preparation is obtained by removal of organic solvent, sterilization and
drying. The fatty-acid-binding alhumin-drug nanoparticle lyophilized
preparation is composed only by albumin, the drugs and the fatty
acids, does not contain any accessories, and has the biological
properties of high nanoparticles integrity and stability in a in vitro
solution and in vivo blood circulation, , significant increase of drug
content in gp60-rich receptor cells or tumor tissues, significant
improvement of the LD50 (half lethal dose) and MTD (maximum
tolerated dose) of load drugs, close of antigen sites of ''packaged'' or
''bound'' proteins, and the like.

TUMOR TREATMENT METHOD FOR BLOCKING TUMOR VASCULATURE BY MEANS OF NANOMATERIAL AND
EXTERNAL RADIATION SOURCE
N publicacin WO2016015173A1 04/02/2016
BEIJING FULLCAN BIO TECHNOLOGY CO LTD [CN]
Solicitantes
Provided is an application of a nanomaterial to the preparation of a tumor vasculature blocking agent, said nanomaterial having all
Resumen
of the following properties: (1) the surface is hydrophilic; (2) the surface has electronegativity; (3) the size of the nanomaterial is
50-250 nm, and the material is rigid, such that it is not prone to passing through the hole in the wall of a tumor vessel and
becoming stuck in said hole; (4) the nanomaterial can absorb external radiation energy, and internally convert same to thermal
energy, and accumulate said thermal energy, causing the morphological structure of said nanomaterial to change dramatically.
During treatment, the described nanomaterial is injected into a tumor-bearing organism, then radiation is applied to the tumor
section, causing the nanomaterial to absorb the radiation energy and its internal temperature to rise rapidly; when the temperature
has risen to a certain level, the morphological structure of the nanomaterial changes (explosion or dramatic volume expansion),
thereby causing the morphological structure or function of the tumor vascular endothelial cells to change, destroying the tumor
vasculature.

Alertas Tecnolgicas

- 39 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY


N publicacin US2016032320A1 04/02/2016
PROTIVA BIOTHERAPEUTICS INC [CA]
Solicitantes
The present invention provides novel, stable lipid particles having a
Resumen
non-lamellar structure and comprising one or more active agents or
therapeutic agents, methods of making such lipid particles, and
methods of delivering and/or administering such lipid particles. More
particularly, the present invention provides stable nucleic acid-lipid
particles (SNALP) that have a non-lamellar structure and that
comprise a nucleic acid (such as one or more interfering RNA),
methods of making the SNALP, and methods of delivering and/or
administering the SNALP.

BIOCHAR PRODUCTS AND METHOD OF MANUFACTURE THEREOF


N publicacin US2016030922A1 04/02/2016
CARBON BASIS COMPANY LTD [CA]
Solicitantes
A method for producing charcoal particles or pellets which use different additives as binders for the biochar pellets. The method
Resumen
includes producing a mixture with charcoal and additives selected from nanocrystalline cellulose, bentonite, and polyvinyl
acetate. The mixture is created by mixing one or more of the additives with charcoal and water. The mixture is then processed in a
pelletizer device. While processing, the surface of the mixture is sprayed with a liquid. Once turned into pellets by way of the
pelletizer device, the resulting pellets are then dried by applying heat to the pellets. The liquid can be water or a solution of water
and sodium borate.
METHODS OF DELIVERING NANOSHELLS INTO SEBACEOUS GLANDS
N publicacin US2016030726A1 04/02/2016
UNIV CALIFORNIA [US]
Solicitantes
Improved methods for treating a sebaceous gland disorder, such as
Resumen
acne, are described. The methods include a) cleaning the skin site with
a solvent by applying immersion low frequency ultrasound to the site;
b) delivering nanoshell particles into the infundibula and sebaceous
glands over a period of time, by applying iontophoresis, low
frequency ultrasound, or electroporation, or a combination thereof,
preferably administering immersion low frequency ultrasound; and c)
thermally activating the nanoshell particles to modify or destroy the
infundibula and sebaceous gland are provided. A sufficient amount of
the nanoshell particles infiltrates spaces about the sebaceous glands
and is exposed to energy to cause the particles to become thermally
activated. Photothermal activation of the nanoshell particles brings
about a physiological change in the sebaceous gland, thereby treating
the sebaceous gland disorder. Preferably, the sebaceous gland is
destroyed. There is minimal to no destruction of normal adjacent
epidermal and dermal structures.

Alertas Tecnolgicas

- 40 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

ON-DEMAND DRUG RELEASE USING MAGNETO-ELECTRIC NANOPARTICLES


N publicacin US2016030724A1 04/02/2016
LIANG PING [US]
Solicitantes
FLORIDA INT UNIV BOARD TRUSTEES [US]
Disclosed herein are methods of delivering drugs to a subject in a
Resumen
controlled release fashion by administering a magento-electric
nanoparticle having ionic bonds to a drug then applying a magnetic
field to weaken the ionic bonds and release the drug.

PEPTIDE-ALBUMIN HYDROGEL PROPERTIES AND ITS APPLICATIONS


N publicacin US2016030629A1 04/02/2016
UNIV KANSAS STATE [US]
Solicitantes
Peptide-albumin hydrogels having a self-assembling, 3-dimensional
Resumen
nanofiber matrix are described. The nanofiber matrix comprises an
amphiphilic peptide and albumin. The peptide comprises a terminal
hydrophobic region, a central turning region, and a terminal
hydrophilic region. Methods of making such hydrogels are also
described, along with methods of using the hydrogels as scaffolding
for tissue engineering, as 3-dimensional cell cultures, and for drug
delivery, encapsulation of active agents (therapeutic cells, molecules,
drugs, compounds), cell transplantation, cell storage, virus culture and
storage.

Alertas Tecnolgicas

- 41 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

TARGETED DELIVERY OF NANOPARTICLES TO EPICARDIAL DERIVED CELLS (EPDC)


N publicacin US2016030600A1 04/02/2016
CROZET MEDICAL GMBH [DE]
Solicitantes
This invention relates to nanoparticles for use in the in vivo
Resumen
diagnostics of epicardial derived cells (EPDCs) to nanoparticles for
use in the treatment of cardiac injury. The invention further relates to
a method for analyzing EPDCs, to a method for labeling EPDCs, and
to a method for transferring a therapeutic agent into an EPDC.

ANTIBODY-NANOPARTICLE CONJUGATES FOR THE TREATMENT OF DRUG ABUSE


N publicacin US2016030593A1 04/02/2016
PETERSON ERIC C [US]
Solicitantes
NANAWARE-KHARADE NISHA [US]
GONZALEZ III GUILLERMO [US]
UNIV ARKANSAS [US]
The present invention generally relates to an antibody composition including antibodies conjugated to nanoparticles. The antibody
Resumen
composition may be used in methods to treat drug use, drug addiction, and effects of drug use.
IMMUNE-POTENTIATING DRUG NANOCARRIERS
N publicacin US2016030588A1 04/02/2016
UNIV MIAMI [US]
Solicitantes
Described herein are nanoparticle-based compositions, kits, methods
Resumen
and platforms for delivering drugs to professional APCs (PAPCs) in
vivo resulting in a robust and specific immune response to a pathogen,
e.g., Leishmania major. The composition, kits, platforms and methods
involve the combined use of MHC targeting and immunogenic
moieties (e.g., PADRE) with dendrimers (e.g., PAMAM and other
dendrimers) as vehicles for the targeted delivery of anti-pathogen
agents (e.g., AmB) to PAPCs via MHC class II molecules expressed
on the surface of such cells such that the anti-pathogen agent is
internalized by the PAPCs. The composition, kits, platforms and
methods described herein provide for specific and efficient delivery of
anti-pathogen agents (e.g., drugs such as AmBisome TM ) to PAPCs
in vivo that results in a reduction of growth or elimination of the
pathogen involving a robust and specific immune response to the
pathogen. The nanocarriers described herein target phagocytes, shuttle
their cargo into these cells, activate CD4 T helper cells, and act as an
adjuvant to enhance immune responses.

Alertas Tecnolgicas

- 42 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

TOLEROGENIC SYNTHETIC NANOCARRIERS.


N publicacin US2016030555A1 04/02/2016
SELECTA BIOSCIENCES INC [US]
Solicitantes
This invention relates, at least in part, to compositions comprising
Resumen
synthetic nanocarriers and immunosuppressants that result in immune
suppressive effects. Such compositions can further comprise antigen
and provide antigen- specific tolerogenic immune responses.

TOLEROGENIC SYNTHETIC NANOCARRIERS.


N publicacin US2016030554A1 04/02/2016
SELECTA BIOSCIENCES INC [US]
Solicitantes
This invention relates, at least in part, to compositions comprising
Resumen
synthetic nanocarriers and immunosuppressants that result in immune
suppressive effects. Such compositions can further comprise antigen
and provide antigen- specific tolerogenic immune responses.

Alertas Tecnolgicas

- 43 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

USE OF PACAP FOR TREATING VIRAL INFECTIONS IN AQUATIC ORGANISMS


N publicacin US2016030519A1 04/02/2016
CT INGENIERIA GENETICA BIOTECH [CU]
Solicitantes
The present invention relates to the use of the pituitary adenylate
Resumen
cyclase-activating polypeptide (PACAP) for treating viral infections
and virus-induced infectious diseases in aquatic organisms. The
effectiveness of PACAP used alone or combined with an antiviral
molecule and administered orally, by injection or by means of
immersion baths has been demonstrated by an increase in the survival
of fish or crustaceans infected with a virus. Moreover, it has been
observed that, following the use thereof, the body weight of the
aforementioned organisms is maintained or increased compared to that
of infected organisms that are not treated with these preparations. By
means of the reverse transcription-polymerase chain reaction of
tissues and organs susceptible to viral infection, it has been shown that
PACAP or combinations containing PACAP reduce the viral load in
infected organisms.

METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS


N publicacin US2016030514A1 04/02/2016
ELIXIRGEN LLC [US]
Solicitantes
The present disclosure relates to methods for increasing telomere
Resumen
length in one or more human cells and/or increasing genome stability
of one or more human cells, for example by contacting one or more
human cells with an agent that increases expression of Zscan4 in the
one or more human cells. Methods of treating a subject in need of
telomere lengthening, treating a disease or condition associated with a
genomic and/or chromosome abnormality, of rejuvenating one or
more human cells, of rejuvenating tissues or organs, and of
rejuvenating a subject in need thereof, for example by contacting one
or more human cells in the subject with an agent that increases
expression of Zscan4, or by administering to a subject in need thereof,
an agent that increases expression of Zscan4 are also provided.

Alertas Tecnolgicas

- 44 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

Sustained-release nanoparticle compositions and methods for using the same


N publicacin US2016030402A1 04/02/2016
UNIV NEBRASKA BY AND BEHALF OF THE UNIVERSITY OF NEBRASKA MEDICAL BOARD OF REGENTS [US]
Solicitantes
The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a
Resumen
vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a
disease or condition.
MTOR INHIBITORS FOR PREVENTION OF INTESTINAL POLYP GROWTH
N publicacin US2016030401A1 04/02/2016
UNIV TEXAS [US]
Solicitantes
Disclosed are methods and compositions for the treatment or
Resumen
prevention of intestinal polyps or prevention of cancer in a patient
who has been identified as being at risk for developing intestinal
polyps or intestinal cancer. The disclosed methods and compositions
include rapamycin, a rapamycin analog, or another such inhibitor of
the target of rapamycin (TOR).

Alertas Tecnolgicas

- 45 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF


N publicacin US2016030349A1 04/02/2016
BOEHRINGER INGELHEIM VETMED [DE]
Solicitantes
The present invention relates to core-shell nanoparticles, methods for
Resumen
their production, and their use, in particular as adjuvants. Generally,
the nanoparticles of the invention comprise a solid core consisting of a
biodegradable polymer and a shell of amphiphilic molecules disposed
about said core.

ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS


N publicacin US2016030346A1 04/02/2016
UNIV NORTH CAROLINA [US]
Solicitantes
An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated
Resumen
nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of
auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body
member. An associated method is also provided.
SOLID LIPID NANOPARTICLES (II)
N publicacin US2016030305A1 04/02/2016
DSM IP ASSETS BV [NL]
Solicitantes
The present invention relates to new (foodgrade) solid lipid nanoparticles, as well as the production of such solid lipid
Resumen
nanoparticles and the use of them.

Alertas Tecnolgicas

- 46 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

VACCINATION COMPOSITION
N publicacin US2016030348A1 04/02/2016
CRISTAL DELIVERY B V [NL]
Solicitantes
The present invention is directed to vaccination composition
Resumen
comprising a particle comprising a polymer matrix incorporating an
adjuvant and/or an antigen, to method of making them and use.
Particularly, the present invention results in adjuvants and/or antigens,
covalently entrapped in or coupled to polymer carriers or polymeric
devices, such as micelles, nanoparticles, microspheres and other types
of polymer devices for controlled release; the adjuvant and/or antigen
are covalently bonded in or to the polymer carriers or polymeric
devices.

A METHOD OF PREPARING AMORPHOUS SOLID DISPERSION IN SUBMICRON RANGE BY CO-PRECIPITATION


N publicacin WO2016016665A1 04/02/2016
HOVIONE INT LTD [CN]
Solicitantes
TURNER CRAIG [GB]
The present invention discloses a method for producing amorphous solid dispersions in a nanoparticulate form, through solvent
Resumen
controlled co-precipitation, using microfluidization/microreaction technology to promote high energy mixing/interaction at a
micro and/or molecular level between the streams involved in the process. Feed streams, solvent and anti-solvent, are fed to an
intensifier pump at individually controlled rates and forced to interact to micro-and/or nano-scale within a microreactor. The
present invention also discloses amorphous solid dispersions obtained by the method of the invention as well as pharmaceutical
compositions containing the same.
NANOPARTICULATE FORMULATION COMPRISING A MPGES-1 INHIBITOR
N publicacin WO2016016861A1 04/02/2016
GLENMARK PHARMACEUTICALS SA [CH]
Solicitantes
The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1
Resumen
("mPGES-1") inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1
inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and
inflammation in a subject.
NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF
N publicacin WO2016016401A1 04/02/2016
BOEHRINGER INGELHEIM VETMED [DE]
Solicitantes
The present invention relates to core-shell nanoparticles, methods for their production, and their use, in particular as adjuvants.
Resumen
Generally, the nanoparticles of the invention comprise a solid core consisting of a biodegradable polymer and a shell of
amphiphilic molecules disposed about said core.

Alertas Tecnolgicas

- 47 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

FUNCTIONAL PARTICLES, PRODUCTION PROCESS AND USES


N publicacin WO2016016867A1 04/02/2016
SMART INOVATION LDA [PT]
Solicitantes
The present invention relates to a process for producing and formulating functional particles made of silica and other materials
Resumen
with active principles or compounds for use in polymers, inks, mortars, ceramics, cements, textiles, pharmaceuticals, varnishes,
paper, clays, cosmetics, sensors and effluents. The present disclosure describes a functional particle to be bonded to a substrate
and comprising: a granule comprising an oxide or hydroxide of an element selected from the following list: silica, magnesium,
zinc, iron, copper, silver, aluminium, gold, titanium or their mixtures, and having a size from 90 nm - 50 nm; a binder comprising
silane-based compounds which binds the outside granule to the substrate; a functional compound or active compound bonded to
the surface of the granule, to the binder, or to both; the functional compound is at least one of the following compounds: a
mosquito or insect repellent, a fungicide, an antimicrobial agent or bactericide; an antimycotic agent, a fire retardant, anti-U.V.
compounds, larvicides, waterproofing agents, vitamins, moisturizing agents, cosmetics, medicinal drugs, mechanical property
enhancers, magnetic property enhancers or mixtures thereof.
Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
N publicacin AU2016200137A1 04/02/2016
SELECTA BIOSCIENCES INC
Solicitantes
This invention relates to compositions, and related methods, of
Resumen
synthetic nanocarriers that target sites of action in cells, such as
antigen presenting cells (APCs), and comprise immunomodulatory
agents that dissociate from the synthetic nanocarriers in a pH sensitive
manner. Also disclosed are compositions and methods relating to
synthetic nanocarriers that encapsulate labile immunomodulatory
agents that dissociate from the synthetic nanocarriers in a pH sensitive
manner.

Alertas Tecnolgicas

- 48 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

STABLE NANOCOMPOSITION COMPRISING DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE
AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
N publicacin EP2978423A1 03/02/2016
BBS NANOTECHNOLOGY LTD [HU]
Solicitantes
A nanoparticulate composition for the targeted therapeutic treatment
Resumen
of tumours. The stable self assembled nanocomposition according to
the invention comprises (i) a carrier and targeting system comprising
an optionally modified polyanion, and optionally a polycation, which
may also be modified; at least one targeting agent which is linked to
either the polycation/modified polycation or the polyanion/modified
polyanion, or both, or to the surface of the nanoparticle; (ii) an active
compound selected from the group of doxorubicin and its
pharmaceutically acceptable salts, especially hydrochloride; and
optionally (iii) at least one complexing agent, a metal ion, a
stabilizer/formulating agent, or a PEGylating agent.; The present
invention furthermore relates to a process for the preparation of the
above-mentioned composition, the therapeutic uses thereof, and
pharmaceutical compositions containing the nanocomposition
according to the invention.

Alertas Tecnolgicas

- 49 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND
PHARMACEUTICAL COMPOSITIONS CONTAINING IT
N publicacin EP2978421A1 03/02/2016
BBS NANOTECHNOLOGY LTD [HU]
Solicitantes
A nanoparticulate composition is disclosed for the targeted therapeutic
Resumen
treatment of tumours. The stable self assembled nanocomposition
according to the invention comprises (i) a carrier and targeting system
comprising an optionally modified polyanion, and optionally a
polycation, which may also be modified; at least one targeting agent
which is linked to either the polycation/modified polycation or the
polyanion/modified polyanion, or both or to the surface of the
nanoparticle; (ii) an active compound selected from the group of
docetaxel and its pharmaceutically acceptable salts and derivatives
especially its hydrates, especially docetaxel trihydrate and docetaxel
trihydrate monohydrochloride; and optionally (iii) at least one
complexing agent, a metal ion and a stabilizer/formulating agent, or a
PEGylating agent. The present invention furthermore relates to a
process for the preparation of the above-mentioned composition, the
therapeutic uses thereof, and pharmaceutical compositions containing
the nanocomposition according to the invention.

A SOLID NANOPARTICLE WITH INORGANIC COATING


N publicacin KR20160013050A 03/02/2016
A nanoparticle having a solid core comprising a biologically active
Resumen
substance, said core being enclosed by an inorganic coating, a method
for preparing the nanoparticle, and the use of the nanoparticle in
therapy. A kit comprising the nanoparticle and a pharmaceutical
composition comprising the nanoparticle.

Alertas Tecnolgicas

- 50 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

STABLE NANOCOMPOSITION COMPRISING EPIRUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND
PHARMACEUTICAL COMPOSITIONS CONTAINING IT
N publicacin EP2978428A1 03/02/2016
BBS NANOTECHNOLOGY LTD [HU]
Solicitantes
A nanoparticulate composition is disclosed for the targeted therapeutic
Resumen
treatment of tumours. The stable self assembled nanocomposition
according to the invention comprises (i) a carrier and targeting system
comprising an optionally modified polyanion, and optionally a
polycation, which may also be modified; at least one targeting agent
which is linked to either the polycation/modified polycation or the
polyanion/modified polyanion, or both; (ii) an active compound
selected from the group of epirubicin and its pharmaceutically
acceptable salts, especially hydrochloride; and optionally (iii) at least
one complexing agent, metal ion and stabilizer/formulating agent. The
invention furthermore relates to a process for the preparation of the
above-mentioned composition, the therapeutic uses thereof, and
pharmaceutical compositions containing the nanocomposition
according to the invention.

PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF


N publicacin KR20160013212A 03/02/2016
The present invention relates to a pharmaceutical composition
Resumen
comprising the combination of (i) a biocompatible nanoparticle and of
(ii) a pharmaceutical compound of interest, to be administered to a
subject in need of such a compound of interest, wherein the
nanoparticle potentiates the compound of interest efficiency. The
longest dimension of the biocompatible nanoparticle is typically
between about 4 and about 500 nm, and its absolute surface charge
value is of at least 10 m V (|10 m V|). The invention also relates to
such a composition for use for administering the compound of interest
in a subject in need thereof, wherein the nanoparticle and the
compound of interest are to be administered in said subject between
more than 5 minutes and about 72 hours one from each other.

Alertas Tecnolgicas

- 51 de 52 -

NANOFRMACOS

Departamento de Patentes e Informacin Tecnolgica


Unidad de Informacin Tecnolgica

STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND
PHARMACEUTICAL COMPOSITIONS CONTAINING IT
N publicacin EP2978420A1 03/02/2016
BBS NANOTECHNOLOGY LTD [HU]
Solicitantes
A nanoparticulate composition is disclosed for the targeted therapeutic
Resumen
treatment of tumours. The stable self assembled nanocomposition
according to the invention comprises (i) a carrier and targeting system
comprising an optionally modified polyanion, and optionally a
polycation, which may also be modified; at least one targeting agent
which is linked to either the polycation/modified polycation or the
polyanion/modified polyanion, or both or to the surface of the
nanoparticle; (ii) paclitaxel as active compound; and optionally (iii) at
least one complexing agent, a metal ion and a stabilizer/formulating
agent or a PEGylating agent. The invention furthermore relates to a
process for the preparation of the above-mentioned composition, the
therapeutic uses thereof, and pharmaceutical compositions containing
the nanocomposition according to the invention.

Alertas Tecnolgicas

- 52 de 52 -

NANOFRMACOS